CD22-directed Antibody Interactions [MoA] - N0000193616
Pharmacologic Class Information
Pharmacologic Code | N0000193616 |
Pharmacologic Name | CD22-directed Antibody Interactions |
Pharmacologic Uses |
|
Pharmacologic Concept | Mechanisms of Action - [MoA] |
Pharmacologic Concept Description | This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept. |
NDC Products with CD22-directed Antibody Interactions
The table contains 1 products whose active ingredient are classified under the same pharmacologic class CD22-directed Antibody Interactions [MoA].
NDC | Proprietary Name | Non-Proprietary Name | Dosage Form | Route Name | Company Name | Status | |
---|---|---|---|---|---|---|---|
0008-0100 | Besponsa | Non-Proprietary Name: Inotuzumab Ozogamicin | Injection, Powder, Lyophilized, For Solution | Intravenous | Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc. | ACTIVE |